Sign in to view content

Baseline Characteristics in the Phase 2 GOLDEN Study of IONIS-FB-LRx, an Investigational Antisense Oligonucleotide Designed to Treat AMD-Associated Geographic Atrophy

Glenn J. Jaffe, MD

Video
Published 2022

Related

Learnings From the Lampalizumab Chroma and Spectri Phase 3 Trials: Effect of Baseline Characteristics on Geographic Atrophy Progression
Carl D. Regillo, MD
Annual Meeting Talks
2018
Common Age-Related Macular Degeneration Genetic Risk Variants and Geographic Atrophy Lesion Growth in the Chroma and Spectri Phase 3 Lampalizumab Trials
Karl G. Csaky, MD, PhD
Annual Meeting Talks
2018
Twelve Month Safety and Efficacy Outcomes from a Phase 2 Study of APL-2 in Patients with Geographic Atrophy
David S. Boyer, MD
Updates from the Field
2017

Category: AMD-Non-Neovascular

See more